Emergent BioSolutions (EBS) Receivables (2010 - 2026)
Emergent BioSolutions (EBS) reported Receivables of $211.2 million for Q2 2026, up 105.6% from $102.7 million a year earlier and up 51.0% from the prior quarter.
Powered by 
Analysis
Emergent BioSolutions (EBS) Receivables (2010 - 2026) Analysis & Trends
At the end of FY2025, Emergent BioSolutions posted Receivables of $102.4 million, down 41.2% from FY2024.
- Receivables has a five-year compound annual growth rate of -18.7% (FY2020 to FY2025).
- By year, Receivables came in at $174.1 million in FY2024 (-28.2%), $242.4 million in FY2023 (+12.0%), $216.4 million in FY2022 (-34.5%) and $330.5 million in FY2021 (+14.3%).
- The Q2 2026 figure ranks as the highest quarterly Receivables since Q1 2025.
- Year over year, Receivables gained in two of the last eight quarters, with an average decline of 13.9%.
- The high point for year-over-year Receivables in five years was Q2 2026 (growth of 105.6%); the low point was Q2 2025 (a decline of 63.2%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $139.9 million (Q1 2026), $102.4 million (Q4 2025) and $168.8 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 23.48 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 19.05 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 13.82 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 12.56 Bn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 9.64 Bn |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 15.68 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 10.23 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | 5.06 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 12.49 Bn |
| 10 | Emergent BioSolutions | 325.34 Mn | -425.56 Mn | 137.20 Mn | 211.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 211.20 Mn |
| Mar 31, 2026 | 139.90 Mn |
| Dec 31, 2025 | 102.40 Mn |
| Sep 30, 2025 | 168.80 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 234.60 Mn |
| Dec 31, 2024 | 174.10 Mn |
| Sep 30, 2024 | 140.50 Mn |
| Jun 30, 2024 | 278.80 Mn |
| Mar 31, 2024 | 275.10 Mn |
| Dec 31, 2023 | 242.40 Mn |
| Sep 30, 2023 | 277.50 Mn |
| Jun 30, 2023 | 341.90 Mn |
| Mar 31, 2023 | 205.70 Mn |
| Dec 31, 2022 | 216.40 Mn |
| Sep 30, 2022 | 261.50 Mn |
| Jun 30, 2022 | 230.10 Mn |
| Mar 31, 2022 | 248.40 Mn |
| Dec 31, 2021 | 330.50 Mn |
| Sep 30, 2021 | 312.20 Mn |
API Access
Emergent BioSolutions Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();